Takayasu arteritis is a chronic, nonspecic, inammatory vasculitis that primarily affects young females [12], and involves the aorta and its major branches. The frequency of renal artery involvement and subsequent hypertension in TA is reported to range from 34% to 85% [13]. PTRA (Fig.23.1) is a well-established endovascular intervention for hemody­namically signicant non-atherosclerotic RAS [14]. Before performing PTRA, adequate anti-inammatory treatment and disease activity control are crucial since active disease is linked to an increased risk of procedure-related complica­tions and a higher risk of restenosis if revascularization is performed in an active disease state [15]. Balloon angio­plasty has demonstrated greater long-term patency and an equivalent clinical outcome compared with the surgery and stenting in hemodynamically signicant RAS caused by Takayasu’s arteritis [16]. It has been found that the results of PTRA are heavily impacted by the lesions length and resid­ual stenosis rate. Restenosis rates reported in literature are up to 9% by angioplasty and 62.5% in the setting of a stent [16]. Hence, stenting is avoided in TA unless there is a vessel recoil with signicant residual stenosis or a ow-limiting dissection ap following balloon dilation.